Logo-bi
Letter to the Editor COVID-19

1. Computational-based drug repurposing methods in COVID-19
Yosef Masoudi-Sobhanzadeh* ORCID
Bioimpacts. 2020;10(3): 205-206. doi: 10.34172/bi.2020.25
PMCID: PMC7416005     PMID: 32793443     Scopus ID: 85089710496    
Article
PDF
Full Text
XML
Cited By:
17
11
19
This letter aims to introduce drug repurposing methods and the existing challenges to detect candidate drugs which may be helpful in controlling COVID-19.
Mini Review

2. Transformative dynamism in pharmaceutical and biomedical research: Complexity of integration of innovative R & D hubs
Yadollah Omidi* ORCID, Hossein Omidian
BioImpacts. 2021;11(3): 227-233. doi: 10.34172/bi.2021.29
PMCID: PMC8314036     PMID: 34336611     Scopus ID: 85109081223    
Article
PDF
Full Text
XML
Cited By:
1
0
1
Transformation of the academic pharmaceutical and biomedical research centers towards innovative R & D hubs is a dynamic nested complex matter, which can be accomplished via a partnership with pharmaceutical and biomedical manufacturers as well as established and emerging contract research organizations.
Original Article

3. Benchmarking different docking protocols for predicting the binding poses of ligands complexed with cyclooxygenase enzymes and screening chemical libraries

Sara Shamsian ORCID, Babak Sokouti, Siavoush Dastmalchi* ORCID
Bioimpacts. 2024;14(2): 29955. doi: 10.34172/bi.2023.29955
PMCID: PMC10945300     PMID: 38505677     Scopus ID: 85175804718    
Article
PDF
Suppl 1
XML
Cited By:
2
0
1

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge